Literature DB >> 20102869

Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.

Dimitrios Th Kremastinos1, Eftihia Hamodraka, John Parissis, Dimitrios Tsiapras, Kleanthi Dima, Alan Maisel.   

Abstract

BACKGROUND: Beta-thalassemia major is a unique disease characterized by early diastolic dysfunction, related exclusively to iron myocardial deposition. N-terminal-proBNP(amino-terminal) (NT-proBNP) and B-type natriuretic peptide (BNP) are sensitive biomarkers for the detection of asymptomatic left ventricular (LV) dysfunction, and they have important diagnostic and prognostic implications. Using beta-thalassemia as a model disease with isolated diastolic dysfunction, we sought to investigate the predictive value of NT-proBNP and BNP levels in comparison with the conventional and new Doppler echocardiography indexes in detecting this disorder.
METHODS: Seventy beta-thalassemia major patients (mean age 27.2 +/- 12.5 years) with normal LV systolic function (mean LV ejection fraction = 59% +/- 6.8%), and 50 healthy age-matched adults (control group: mean age 25.5 +/- 10.1 years, mean LV ejection fraction = 60% +/- 4.5%) were included. All subjects were studied thoroughly by tissue Doppler echocardiography and blood samples were taken for plasma NT-proBNP and BNP measurements at the same time. To examine LV diastolic function, patients were divided in 3 groups according to the E mitral/E mitral annulus ratio (E/E'): group A, patients without diastolic dysfunction: E/E' ratio <8; group B, patients with suspected diastolic dysfunction: E/E' ratio 8 to 15; group C, patients with documented diastolic dysfunction: E/E' ratio, >15.
RESULTS: NT-proBNP and BNP levels were higher in thalassemic patients compared with the control group (NT-proBNP levels: 80 +/- 19 vs 21 +/- 4 pg/mL, P < .001; BNP levels: 34 +/- 6 vs 9 +/- 3 pg/mL, P < .001). NT-proBNP levels showed a statistically significant increase in group C in comparison to groups A and B, which was also detected between groups A and B (A vs B: P < .05). BNP levels were also significantly increased in group C in comparison to the other 2 groups, but there was no statistically significant difference between groups A and B. Using receiver operating characteristic analysis, NT-proBNP at a cut point of 49.2 pg/mL was highly accurate (area under curve: 0.97, P < .001) in ruling out diastolic dysfunction (E/E' <8) with a sensitivity of 93.7% and a specificity of 89.6%.
CONCLUSIONS: BNP and NT-proBNP levels are significantly increased in documented left ventricular diastolic dysfunction, while NT-proBNP seems to have better predictive value in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102869     DOI: 10.1016/j.ahj.2009.10.025

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Combined histological and hematological assessment of iron-induced organ damage in a gerbil model of iron overload.

Authors:  Man Wang; Rong-Rong Liu; Cong-Jun Wang; Wei Kang; Gao-Hui Yang; Wu-Ning Zhong; Yong-Rong Lai
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Determining Nt-proBNP Levels with Diastolic Dysfunction in Thalassemia Major Patients.

Authors:  Mable Misha Singh; Ravindra Kumar; Satyendra Tewari; Sarita Agarwal
Journal:  J Pediatr Genet       Date:  2017-05-11

3.  Correlation of N-terminal pro-B-type natriuretic peptide levels and cardiac magnetic resonance imaging T2* in patients with β-thalassaemia major.

Authors:  Valiollah Mehrzad; Amirreza Sajjadieh Khajouei; Elaheh Fahami
Journal:  Blood Transfus       Date:  2016-01-13       Impact factor: 3.443

4.  Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

Authors:  Steven E Lipshultz; David C Landy; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M Rovitelli; Cindy Proukou; M Jacob Adams; Tracie L Miller
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Evaluation of tissue doppler echocardiography and T2* magnetic resonance imaging in iron load of patients with thalassemia major.

Authors:  Mehrdad Saravi; Ahmad Tamadoni; Rozita Jalalian; Hassan Mahmoodi-Nesheli; Mosatafa Hojati; Saeed Ramezani
Journal:  Caspian J Intern Med       Date:  2013

Review 6.  Advancement of echocardiography for surveillance of iron overload cardiomyopathy: comparison to cardiac magnetic resonance imaging.

Authors:  M Jason Zimmerman; Douglas R Rosing; Yukitaka Shizukuda
Journal:  J Echocardiogr       Date:  2021-03-26

7.  A Comparison Between MRIT2 and NT-ProBNP in Early Detection of Heart Diseases in Thalassemia Major Patients: A Cross-Sectional Study.

Authors:  Kourosh Goudarzipour; Parinaz Alizadeh; Hesameddin Hoseini Tavassol; Reyhaneh Kazemi; Peyman Eshghi; Saeed Mojtahedzadeh
Journal:  Indian J Hematol Blood Transfus       Date:  2017-02-27       Impact factor: 0.900

8.  Preserved cardiorespiratory function and NT-proBNP levels before and during exercise in patients with recent onset of rheumatoid arthritis: the clinical challenge of stratifying the patient cardiovascular risks.

Authors:  A Zoli; S Bosello; G Comerci; N Galiano; A Forni; F Loperfido; G F Ferraccioli
Journal:  Rheumatol Int       Date:  2015-11-19       Impact factor: 2.631

9.  Correlation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic dysfunction.

Authors:  Hui Gong; Xin Wang; Yi-Jun Shi; Wen-Jing Shang; Y I Ling; Li-Jian Pan; Hai-Ming Shi
Journal:  Exp Ther Med       Date:  2016-03-30       Impact factor: 2.447

10.  The pro-BNP Serum Level and Echocardiographic Tissue Doppler Abnormalities in Patients with Beta Thalassemia Major.

Authors:  Taysir S Garadah; Najat Mahdi; Salah Kassab; Isa Al Shoroqi; Ahmed Abu-Taleb; Anwer Jamsheer
Journal:  Clin Med Insights Cardiol       Date:  2010-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.